A Phase 1 Dose-Escalation Study of SCH 900776 as Monotherapy and in Combination With Gemcitabine in Subjects With Advanced Solid Tumors or Lymphoma.

Trial Profile

A Phase 1 Dose-Escalation Study of SCH 900776 as Monotherapy and in Combination With Gemcitabine in Subjects With Advanced Solid Tumors or Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs MK 8776 (Primary) ; Gemcitabine
  • Indications Hodgkin's disease; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Merck & Co
  • Most Recent Events

    • 22 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Apr 2011 Planned End Date changed from 1 Mar 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
    • 31 Mar 2011 Planned End Date changed from 1 Oct 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top